BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 35309357)

  • 1. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
    Shafer P; Kelly LM; Hoyos V
    Front Immunol; 2022; 13():835762. PubMed ID: 35309357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Strategies in TCR-Engineered T Cells.
    Wei F; Cheng XX; Xue JZ; Xue SA
    Front Immunol; 2022; 13():850358. PubMed ID: 35432319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
    Hiltensperger M; Krackhardt AM
    Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joining Forces for Cancer Treatment: From "TCR versus CAR" to "TCR and CAR".
    Teppert K; Wang X; Anders K; Evaristo C; Lock D; Künkele A
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of CD8
    Sun Y; Li F; Sonnemann H; Jackson KR; Talukder AH; Katailiha AS; Lizee G
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TCR-based Chimeric Antigen Receptor.
    Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
    Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell Receptor Engineered Lymphocytes for Cancer Therapy.
    Rollins MR; Spartz EJ; Stromnes IM
    Curr Protoc Immunol; 2020 Jun; 129(1):e97. PubMed ID: 32432843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
    Biernacki MA; Brault M; Bleakley M
    Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
    Mensali N; Myhre MR; Dillard P; Pollmann S; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
    Cancer Immunol Immunother; 2019 Aug; 68(8):1235-1243. PubMed ID: 31214732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
    Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 18. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
    Akatsuka Y
    Front Immunol; 2020; 11():257. PubMed ID: 32184779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
    Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
    J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.